Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin dosing optimization in septic ICU patients with augmented renal clearance
IRCT20100228003449N24Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vancomycin in sepsis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Attainment of vancomycin target concentration, Clearance of systemic inflammatory responses and 1 more. Started Jul 2018; status: completed.
02
Drugs
vancomycin
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20100228003449N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100228003449N24.